Regulation of the pathological vasculature of malignant astrocytomas by angiopoietin-1.

Malignant astrocytomas are the most common and highly vascularized of all primary adult brain tumors. The histopathological hallmarks of malignant astrocytomas are microvascular proliferation and formation of vascular entities, which are referred to as "glomeruloid bodies." The significance of glomeruloid bodies and the molecular mechanisms driving the abnormal vascular architecture in malignant astrocytomas are not understood. We have observed that overexpression of angiopoietin-1 (Ang1) in both subcutaneous and intracranial xenograft models of malignant astrocytomas reproduces many of the vascular features of these tumors, including glomeruloid bodies. To confirm that the formation of glomeruloid bodies was directly dependent on Ang1, we performed experiments where levels of Ang1 expression were regulated under tetracycline control, and we found a direct correlation between levels of Ang1 expression and the occurrence of glomeruloid bodies in xenografts. Additionally, we inhibited the action of Ang1 by blocking its cognate receptor Tie2, and we found that the formation of glomeruloid bodies was inhibited. Collectively, these results support our hypothesis that Ang1 is a key molecular regulator of pathological vascularization characteristic of malignant astrocytomas.

[1]  A. Gregory Sorensen,et al.  Angiogenesis in brain tumours , 2007, Nature Reviews Neuroscience.

[2]  P. Shannon,et al.  Role of Ang1 and Its Interaction with VEGF‐A in Astrocytomas , 2004, Journal of neuropathology and experimental neurology.

[3]  G. Zadeh,et al.  Targeting the Tie2/Tek receptor in astrocytomas. , 2004, The American journal of pathology.

[4]  P. Wesseling,et al.  Angiogenesis in brain tumors; pathobiological and clinical aspects , 1997, Journal of Neuro-Oncology.

[5]  Daniel J. Dumont,et al.  Tek/Tie2 Signaling: New and Old Partners , 2004, Cancer and Metastasis Reviews.

[6]  G. Zadeh,et al.  Angiogenesis in Nervous System Disorders , 2003, Neurosurgery.

[7]  Gelareh Zadeh,et al.  Molecular regulators of angiogenesis in the developing nervous system and adult brain tumors (review). , 2003, International journal of oncology.

[8]  Johannes Vogel,et al.  Heterologous Expression of Human VEGF165 in Rat Brain: Dose-Dependent, Heterogeneous Effects on CBF in Relation to Vascular Density and Cross-Sectional Area , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  G. Zadeh,et al.  Neoangiogenesis in human astrocytomas: expression and functional role of angiopoietins and their cognate receptors. , 2003, Frontiers in bioscience : a journal and virtual library.

[10]  D. Dumont,et al.  The angiopoietins and Tie2/Tek: adding to the complexity of cardiovascular development. , 2002, Seminars in cell & developmental biology.

[11]  L. Ellis,et al.  Differential expression of angiopoietin‐1 and angiopoietin‐2 in colon carcinoma , 2001, Cancer.

[12]  T. Suda,et al.  Role for Angiogenesis Expression of Angiopoietin-2 in Human Glioma Cells and Its Updated Version , 2001 .

[13]  M. Mrksich,et al.  Direct Cell Adhesion to the Angiopoietins Mediated by Integrins* , 2001, The Journal of Biological Chemistry.

[14]  F. Lang,et al.  Conditional gene expression in human intracranial xenograft tumors. , 2001, BioTechniques.

[15]  D. Schiffer,et al.  Expression of Angiopoietin-1 in Human Glioblastomas Regulates Tumor-Induced Angiogenesis: In Vivo and In Vitro Studies , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[16]  S. Kitano,et al.  Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: possible in vivo regulation via induction of proteases. , 2001, Cancer research.

[17]  Erwin G. Van Meir,et al.  Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. , 2001, The American journal of pathology.

[18]  E. Manseau,et al.  Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery. , 2001, The American journal of pathology.

[19]  I. Stamenkovic,et al.  Angiopoietin-2 is implicated in the regulation of tumor angiogenesis. , 2001, The American journal of pathology.

[20]  T. Acker,et al.  Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor‐2 dominant‐negative receptor mutants , 2001, International journal of cancer.

[21]  P. Shannon,et al.  Expression and hypoxic regulation of angiopoietins in human astrocytomas. , 2001, Neuro-oncology.

[22]  S. McLeskey,et al.  Expression and function of angiopoietin-1 in breast cancer , 2000, British Journal of Cancer.

[23]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[24]  Ji-Hye Kim,et al.  Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway , 2000, Oncogene.

[25]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[26]  R. Weksberg,et al.  Expression of p57(KIP2) potently blocks the growth of human astrocytomas and induces cell senescence. , 2000, The American journal of pathology.

[27]  G. Koh,et al.  Characterization and Expression of a Novel Alternatively Spliced Human Angiopoietin-2* , 2000, The Journal of Biological Chemistry.

[28]  S. Karpatkin,et al.  Identification of a family of alternatively spliced mRNA species of angiopoietin-1. , 2000, Blood.

[29]  J. Kim,et al.  Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway. , 2000, Circulation research.

[30]  Thomas N. Sato,et al.  Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. , 1999, Science.

[31]  G. Yancopoulos,et al.  In Situ Expression of Angiopoietins in Astrocytomas Identifies Angiopoietin-2 as an Early Marker of Tumor Angiogenesis , 1999, Experimental Neurology.

[32]  G. Yancopoulos,et al.  New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF , 1999, Oncogene.

[33]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[34]  G. Koh,et al.  Angiopoietin‐1 is an apoptosis survival factor for endothelial cells , 1999, FEBS letters.

[35]  K. Plate,et al.  Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. , 1998, The American journal of pathology.

[36]  Thomas N. Sato,et al.  Increased vascularization in mice overexpressing angiopoietin-1. , 1998, Science.

[37]  P. Carmeliet,et al.  Insights in Vessel Development and Vascular Disorders Using Targeted Inactivation and Transfer of Vascular Endothelial Growth Factor, the Tissue Factor Receptor, and the Plasminogen System , 1997, Annals of the New York Academy of Sciences.

[38]  J. Chason,et al.  Surgical Pathology of the Nervous System and Its Coverings , 1983 .

[39]  R. Anderson,et al.  Surgical Pathology of the Nervous System and Its Coverings , 1977 .